USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: APEX BIOMEDICAL COMPANY, LLC
Address: 501 N GRAHAM, SUITE 250
PORTLAND, OR 97227-1651
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $393,555.00 3
STTR Phase II $595,571.00 1

Award List:

A cost-effective bioreactor to advance functional tissue engineering of cartilage

Award Year / Program / Phase: 2010 / STTR / Phase I
Agency: HHS
Research Institution: Legacy Clinical Research/Technology Ctr
Principal Investigator: Trevor J. Lujan – 208-283-3811
Award Amount: $100,175.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develop replacement cartilage using tissue engineering (TE) technologies.Although TE cartilage presently lacks the… More

Advanced Bicycle Helmet Technology for Prevention of Traumatic Brain Injury

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: LEGACY EMANUEL HOSPITAL
Principal Investigator: Michael Bottlang – 503-413-5457
Award Amount: $144,932.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Traumatic brain injury (TBI) is an acquired neurological disorder that can cause long-lasting disability with limited treatment options. Therefore preventative strategies must be emphasized in high-risk activities to reduce the individual and societal burden… More

Advanced Plate Osteosynthesis Technology to Promote Healing of Bone Fractures

Award Year / Program / Phase: 2012 / STTR / Phase I
Agency: HHS
Research Institution: EMANUEL HOSPITAL AND HEALTH CENTER
Principal Investigator: Michael Bottlang – 503-413-5457
Award Amount: $148,448.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Each year, over 6 million fractures are treated in the United States at a cost in excess of 13 billion. Between 5-8% of these fractures experience complications, particularly in the steadily increasing population withosteoporosis. By providing better fixation… More

A Cost-effective Bioreactor to Advance Functional Tissue Engineering of Cartilage

Award Year / Program / Phase: 2012 / STTR / Phase II
Agency: HHS
Research Institution: EMANUEL HOSPITAL AND HEALTH CENTER
Principal Investigator: Michael Bottlang – 503-413-5457
Award Amount: $595,571.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develo replacement cartilage using tissue engineering (TE) technologies.Although TE cartilage currently lacks the… More